TSE:TRL - Trilogy International Partners Stock Price, Forecast & News

Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."

Trilogy International Partners declared an annual dividend on Monday, April 15th. Shareholders of record on Monday, May 6th will be given a dividend of 0.02 per share on Monday, May 6th. This represents a yield of 0.86%. The ex-dividend date is Monday, April 15th. View Trilogy International Partners' Dividend History.

Trilogy International Partners is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Trilogy International Partners.

2 analysts have issued 1-year price objectives for Trilogy International Partners' stock. Their forecasts range from C$3.25 to C$3.50. On average, they expect Trilogy International Partners' stock price to reach C$3.38 in the next twelve months. This suggests a possible upside of 98.5% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.

Headlines about TRL stock have been trending very negative on Friday, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Trilogy International Partners earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Trilogy International Partners.

Some companies that are related to Trilogy International Partners include BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Recce Pharmaceuticals (RCE), NanoViricides (NNVC), Pharmaxis (PXS), Vita Life Sciences (VLS), Futura Medical (FUM), Avivagen (VIV), Patrys (PAB), Antisense Therapeutics (ANP), China Pharma (CPHI), Sareum (SAR), Cathay International (CTI) and N4 Pharma (N4P).

Based on aggregate information from My MarketBeat watchlists, some companies that other Trilogy International Partners investors own include Acerus Pharmaceuticals (ASP), Merck & Co., Inc. (MRK), Millicom International Cellular (MIICF), Oncolytics Biotech (ONCYF), Emera (EMA), Glacier Bancorp (GBCI), Fibrocell Science (FCSC), CytomX Therapeutics (CTMX), CSX (CSX) and Check Cap (CHEK).

Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

One share of TRL stock can currently be purchased for approximately C$1.70.

Trilogy International Partners has a market capitalization of C$98.64 million and generates C$734.77 million in revenue each year. Trilogy International Partners employs 1,821 workers across the globe.View Additional Information About Trilogy International Partners.

The official website for Trilogy International Partners is http://www.trilogy-international.co.../.

Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.